Myeloproliferative Neoplasms (MPN) Overview

Save information for later
Sign Up

Learn About Myeloproliferative Neoplasms (MPN)

What is the definition of Myeloproliferative Neoplasms (MPN)?
Myeloproliferative neoplasms are rare blood cancers caused by the body making too many red blood cells, white blood cells, or platelets. There are several types of myeloproliferative neoplasms, including chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia.
What are the symptoms of Myeloproliferative Neoplasms (MPN)?
Symptoms of myeloproliferative neoplasms may not appear for years. Symptoms of myeloproliferative neoplasms depend on the type. The most common symptom is discomfort or pressure on the left side below the ribs due to an enlarged spleen. Other symptoms may include bone pain; night sweats; fever; fatigue; bruising easily; loss of appetite; unexplained weight loss; unexplained bleeding; blood in the urine; headaches; dizziness; blurred or double vision; pale or itchy skin; abdominal fullness; reddened face; weakness; shortness of breath; hearing problems; cough; swelling of the face, throat, hands or feet; muscle pain; and diarrhea.
Not sure about your diagnosis?
Check Your Symptoms
What are the different types of Myeloproliferative Neoplasms (MPN)?

Common conditions include: Myelofibrosis

What are the current treatments for Myeloproliferative Neoplasms (MPN)?
There is currently no cure for myeloproliferative neoplasms. Treatment for myeloproliferative neoplasms is focused on relieving the symptoms and preventing complications. Treatments for myeloproliferative neoplasms include watchful waiting, phlebotomy, platelet apheresis, transfusion therapy, chemotherapy, radiation therapy, drug therapy, immunotherapy, targeted therapy, chemotherapy, and stem cell transplant.
Who are the top Myeloproliferative Neoplasms (MPN) Local Doctors?
Ruben A. Mesa
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Ruben A. Mesa
Hematology | Oncology
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Ruben A. Mesa
Hematology | Oncology

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Mesa is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is currently accepting new patients.

Mario Cazzola
Elite in Myeloproliferative Neoplasms (MPN)
Mario Cazzola
Elite in Myeloproliferative Neoplasms (MPN)
Mario Cazzola
Rome, IT 

Mario Cazzola practices in Rome, Italy. Mr. Cazzola is rated as an Elite expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Martin Griesshammer
Elite in Myeloproliferative Neoplasms (MPN)
Martin Griesshammer
Elite in Myeloproliferative Neoplasms (MPN)
Martin Griesshammer
Minden, NW, DE 

Martin Griesshammer practices in Minden, Germany. Mr. Griesshammer is rated as an Elite expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Splenomegaly, Essential Thrombocythemia, and Bone Marrow Transplant.

View All Doctors
What are the latest Myeloproliferative Neoplasms (MPN) Clinical Trials?
A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).

View All Clinical Trials